PTJ
FNCH

Paul Tudor Jones’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Paul Tudor Jones’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-575
Closed -$279K – 2063
2021
Q1 		$279K Buy
+575
New +$293K 0.01% 1332

Other funds holding FNCH

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
TA
TRB Advisors New York $233M AUM 14.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paul Tudor Jones's FNCH Position: Q2 2021 in Review

Paul Tudor Jones sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2021, closing a stake of 575 shares — an estimated $279K sold.

Paul Tudor Jones first reported a position in FNCH in Q1 2021 and held it in 1 quarter. The position peaked at $279K in Q1 2021. 45 funds tracked by Wall St. Rank hold FNCH as of Q2 2021.

  • Paul Tudor Jones reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 575 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2021, an estimated $279K.
  • Paul Tudor Jones first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Paul Tudor Jones's Finch Therapeutics Group, Inc. Common Stock position peaked at $279K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2021.

Based on Tudor Investment Corp's 13F filing for Q2 2021, filed 16 Aug 2021.